239 related articles for article (PubMed ID: 27463838)
1. Defeat mutant KRAS with synthetic lethality.
Pang X; Liu M
Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
[TBL] [Abstract][Full Text] [Related]
2. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
3. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
4. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
5. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
6. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
7. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
10. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
Elife; 2018 Nov; 7():. PubMed ID: 30475204
[TBL] [Abstract][Full Text] [Related]
11. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment.
Zeitouni D; Pylayeva-Gupta Y; Der CJ; Bryant KL
Cancers (Basel); 2016 Apr; 8(4):. PubMed ID: 27096871
[TBL] [Abstract][Full Text] [Related]
12. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethal genetic screens in Ras mutant cancers.
Yu B; Luo J
Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
[TBL] [Abstract][Full Text] [Related]
14. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
[TBL] [Abstract][Full Text] [Related]
15. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
Huang S; Ren X; Wang L; Zhang L; Wu X
Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
[TBL] [Abstract][Full Text] [Related]
16. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
17. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
18. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
19. Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.
Johnson C; Burkhart DL; Haigis KM
Cancer Discov; 2022 Apr; 12(4):913-923. PubMed ID: 35373279
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
Wood K; Hensing T; Malik R; Salgia R
JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
